home · filing · 0001438133-23-000032
8-K filed February 22, 2023, 6:59 PM ET
ticker TNDM
CIK 0001438133
leadership
confidence high
sentiment neutral
materiality 0.60
Rebecca Robertson to succeed Kim Blickenstaff as Chair of Tandem Diabetes Board effective March 1, 2023
TANDEM DIABETES CARE INC
Kim Blickenstaff steps down as Chair but remains a board member; served as Chair since March 2020.
Rebecca Robertson, board member since 2019 and General Partner at Versant Ventures, appointed Chair.
No separate Lead Independent Director designated because Robertson is an independent director.
2022 cash bonuses for named executives paid at 50.8% of target; CEO Sheridan received $359,418.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2023-03-01
Filed February 22, 2023, 6:59 PM ET
Rebecca Robertson will succeed Kim D. Blickenstaff as Chair of the Board of Directors (the “Board”), effective March 1, 2023.
Effective 2023-03-01
Filed February 22, 2023, 6:59 PM ET
Mr. Allen will transition from the role of Lead Independent Director to a member of the Board.
Effective 2023-03-01
Successor Rebecca Robertson
Filed February 22, 2023, 6:59 PM ET
Mr. Blickenstaff will transition from the role of Chair of the Board to a member of the Board
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
TANDEM DIABETES CARE INC reported financial results for quarter and year ended December 31, 2022.
Period quarter and year ended December 31, 2022
Result reported results
Exact text from the filing
On February 22, 2023, we issued a press release reporting our f inancial results for the quarter and year ended December 31, 2022.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rebecca Robertson was appointed as Chair of the Board at TANDEM DIABETES CARE INC.
Action appointed
Role Chair of the Board
Exact text from the filing
Rebecca Robertson will succeed Kim D. Blickenstaff as Chair of the Board of Directors (the “Board”), effective March 1, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Allen changed role as Lead Independent Director at TANDEM DIABETES CARE INC.
Action transitioned
Role Lead Independent Director
Exact text from the filing
Mr. Allen will transition from the role of Lead Independent Director to a member of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kim D. Blickenstaff changed role as Chair of the Board at TANDEM DIABETES CARE INC.
Action transitioned
Role Chair of the Board
Exact text from the filing
Mr. Blickenstaff will transition from the role of Chair of the Board to a member of the Board
View on SEC.gov
Source: SEC EDGAR
accession 0001438133-23-000032
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.